GB Sciences, Inc. (GBLX)

USD 0.0

(0.0%)

Market Cap (In USD)

122.12 Thousand

Revenue (In USD)

-

Net Income (In USD)

-1.36 Million

Avg. Volume

104.61 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-5-0.0135
PE
-0.03
EPS
-0.01
Beta Value
0.604
ISIN
US3615441090
CUSIP
361544109
CIK
1165320
Shares
407071000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Andrea Small-Howard M.B.A., MBA, Ph.D.
Employee Count
-
Website
https://www.gbsciences.com
Ipo Date
2008-05-12
Details
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.